2,795 results on '"Wiendl, Heinz"'
Search Results
2. Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)
3. GateNet: A novel Neural Network Architecture for Automated Flow Cytometry Gating
4. [18F]DPA-714-PET-MRI reveals pronounced innate immunity in human anti-LGI1 and anti-CASPR2 limbic encephalitis
5. Neuronal Mitochondrial Calcium Uniporter (MCU) Deficiency Is Neuroprotective in Hyperexcitability by Modulation of Metabolic Pathways and ROS Balance
6. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
7. Severe CSF immune cell alterations in cryptococcal meningitis gradually resolve during antifungal therapy
8. Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis
9. Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment
10. Serum neurofilament light and white matter characteristics in the general population: a longitudinal analysis
11. Translational imaging of TSPO reveals pronounced innate inflammation in human and murine CD8 T cell–mediated limbic encephalitis
12. Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort
13. Ambulante spezialfachärztliche Versorgung (ASV) für die multiple Sklerose: Positionspapier der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) auf der Basis gegenwärtiger Versorgungsdefizite und -hürden („white paper“)
14. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
15. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
16. GateNet: A novel neural network architecture for automated flow cytometry gating
17. Chemokine-mediated cell migration into the central nervous system in progressive multifocal leukoencephalopathy
18. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations
19. A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis
20. Supporting the differential diagnosis of connective tissue diseases with neurological involvement by blood and cerebrospinal fluid flow cytometry
21. Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies
22. Bruton tyrosine kinase inhibitors for multiple sclerosis
23. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)
24. Classification of neurological diseases using multi-dimensional cerebrospinal fluid analysis
25. Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis
26. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study
27. Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke
28. Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis
29. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
30. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis
31. NOX4-derived ROS are neuroprotective by balancing intracellular calcium stores
32. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.
33. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis.
34. Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction – A systematic review and meta-analysis
35. Review and meta-analysis of neuropsychological findings in autoimmune limbic encephalitis with autoantibodies against LGI1, CASPR2, and GAD65 and their response to immunotherapy
36. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis
37. Bcl6 controls meningeal Th17–B cell interaction in murine neuroinflammation
38. Functional Signature of LRP4 Antibodies in Myasthenia Gravis
39. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients with Relapsing Multiple Sclerosis: Results from Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials (P6-6.011)
40. The Bruton’s Tyrosine Kinase Inhibitor Remibrutinib Exhibits No Impact on Serum Immunoglobulin Levels: Insights from Chronic Spontaneous Urticaria (P10-6.018)
41. Prognostic Value of On-treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People with Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials (S42.003)
42. Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010)
43. Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)
44. Outcomes of COVID-19 in Ofatumumab-treated Patients with RMS: Data from the ALITHIOS Open-label Extension Study (P1-6.010)
45. B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights from ASCLEPIOS I and II Trials (P9-6.002)
46. The dilemma of neuroprotection trials in times of successful endovascular recanalization
47. Résultats de l’étude d’extension NOVA évaluant la préférence des patients pour l’administration sous-cutanée (SC) versus intraveineuse (IV) de natalizumab (NTZ) avec le schéma Q6W (toutes les 6 semaines)
48. Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies
49. What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?
50. Neonatal Fc Receptor–Targeted Therapies in Neurology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.